Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19), у детей. Версия 2

С целью обеспечения детского населения эффективной медицинской помощью в условиях пандемии новой коронавирусной инфекции Минздравом России совместно с профессиональными ассоциациями и экспертами в области педиатрии, инфекционных болезней и реанимации были переработаны методические рекомендации «Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19), у детей». При разработке документа был учтен практический опыт не только специалистов нашей страны, но и зарубежных коллег. Особое внимание уделено доказательной базе представленных данных, а также вопросам эффективности и безопасности лекарственных препаратов, применяемых при лечении данной инфекции и ее осложнений. В статье на основании указанных методических рекомендаций авторы освещают вопросы профилактики, диагностики, лечения патологических состояний, обусловленных COVID-19. Тактика ведения пациента представлена в зависимости от возраста и степени тяжести течения болезни, терапия рассмотрена с позиций этиологической, патогенетической и симптоматической направленности.

1. Технические руководящие указания ВОЗ. Наименование заболевания, вызванного коронавирусом (COVID-19), и вирусного возбудителя. Доступно по: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Ссылка активна на 12.04.2020.

2. Постановление Правительства Российской Федерации от 31 января 2020 N 66 «О внесении изменения в перечень заболеваний, представляющих опасность для окружающих». Доступно по: http://publication.pravo.gov.ru/Document/View/0001202002030005. Ссылка активна на 12.04.2020.

3. New study on COVID-19 estimates 5.1 days for incubation period. The Johns Hopkins Bloomberg School of Public Health, March 9, 2020. Available online: https://www.jhsph.edu/news/news-releases/2020/new-study-on-COVID-19-estimates-5-daysfor-incubation-period.html.

4. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582. doi: 10.7326/M20-0504.

5. Министерство здравоохранения Российской Федерации. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 4 (27.03.2020). Доступно по: https://static-3.rosminzdrav.ru/system/attachments/attaches/000/049/881/original/COVID19_recomend_v4.pdf. Ссылка активна на 12.04.2020.

6. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior or opharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574. doi: 10.1016/S1473-3099(20)30196-1.

7. Shen K, Yang Y. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr. 2020;16(3)219–221. doi: 10.1007/s12519-020-00344-6.

8. Scott D. The Covid-19 risks for different age groups, explained. Vox. 23.03.2020. Available online: https://www.vox.com/2020/3/23/21190033/coronavirus-covid-19-deaths-by-age.

9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.

10. Zhu N, Zhang D, Wang W, et al. A novel Coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017.

11. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.

12. Baez D. Clinical findings of 6 children with COVID-19, risks factors associated with COVID- 19 death, and detection of SARSCoV-2 in different clinical specimens. Mar 13, 2020. Available online: http://www.anmco.it/uploads/u_cms/media/2020/3/b0f67d369884729177067cdc663b497c.pdf.

13. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 Coronavirus Disease in China. Pediatrics. 2020. Available online: https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf.

14. Lu X, Liqiong Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663–1665. doi: 10.1056/NEJMc2005073.

15. Chan J-W, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9.

16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.

17. Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–1741. doi: 10.1111/all.14238.

18. Boulos MN, Geraghty EM. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. Int J Health Geogr. 2020;19(1):8. doi: 10.1186/s12942-020-00202-8.

19. Wang S, Guo L, Chen L, et al. A case report of neonatal COVID-19 infection in China. Clin Infect Dis. 2020;ciaa225. doi: 10.1093/cid/ciaa225.

20. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–815. doi: 10.1016/S0140-6736(20)30360-3.

21. The Daily Star. Coronavirus suspicion: 7-month-old baby sent to Dhaka from isolation ward in Kushtia. Mar 26, 2020. Available online: https://www.thedailystar.net/coronavirus-suspicion-inkushtia-7-month-old-baby-isolation-ward-1886209.

22. WHO recommendation. Getting your workplace ready for COVID-19. Feb 26, 2020. Available online: https://www.who.int/docs/default-source/coronaviruse/getting-workplace-ready-forcovid-19.pdf?sfvrsn=359a81e7_6.

23. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7), Chin Med J (Engl). 2020;133(9):1087–1095. doi: 10.1097/CM9.0000000000000819.

24. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282.

25. Velthuis AJ, van den Worm, Sims AC, et al. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoSPathog. 2010;6(11):e1001176. doi: 10.1371/journal.ppat.1001176.

26. Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. doi: 10.1016/j.ijantimicag.2020.105949.

27. Chang R, Sun W. Repositioning chloroquine as ideal antiviral prophylactic against COVID-19 — time is now. Preprints. 2020;2020030279. doi: 10.20944/preprints202003.0279.v1.

28. Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection. Recommendation. Mar 22, 2020. Available online: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf.

29. National Taskforce for COVID-19 Advisory on the use of hydroxychloroquine as prophylaxis for SARS-CoV-2 infection. 2020. Available online: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdfWorcester S. COVID-19 characteristics differ in children vs adults. 2020. Available online: https://www.medscape.com/viewarticle/926805.

30. Sarma P, Prajapat M, Avti P, et al. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol. 2020;52(1):1–5. doi: 10.4103/ijp.IJP_119_20.

31. Ong SW, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020;323(16):1610–1612. doi: 10.1001/jama.2020.3227.

32. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502–505. doi: 10.1038/s41591-020-0817-4.

33. Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 2020;e200878. doi: 10.1001/jamapediatrics.2020.0878.

34. Wang J, Qi H, Bao L, et al. A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units. Lancet Child Adolesc Health. 2020;4(4):258–259. doi: 10.1016/S2352-4642(20)30040-7.

35. Qin C, Zhou L, Hu Z, at al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;ciaa248. doi: 10.1093/cid/ciaa248.

36. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address: https://www.lancovid.org.Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;101623. doi: 10.1016/j.tmaid.2020.101623.

37. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med. 2020;58(7):1135–1138. doi: 10.1515/cclm-2020-0272.

38. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;ciaa310. doi: 10.1093/cid/ciaa310.

39. Soldati G, Smargiassi A, Inchingolo R, et al. Is there a role for lung ultrasound during the COVID-19 pandemic? J Ultrasound Med. 2020;39(7):1459–1462. doi: 10.1002/jum.15284.

40. Islam M, Levitus M, Eisen L, et al. Lung ultrasound for the diagnosis and management of acute respiratory failure. Lung. 2020;198(1):1–11. doi: 10.1007/s00408-019-00309-1.

41. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16(3):240–246. doi: 10.1007/s12519-020-00345-5.

42. COVID-19 and breastfeeding. WHO Position Paper. Available online: https://www.euro.who.int/__data/assets/pdf_file/0010/437788/breastfeeding-COVID-19.pdf.

43. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088–1095. doi: 10.1111/apa.15270.

44. Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr. 2020;16(3):223–231. doi: 10.1007/s12519-020-00343-7.

45. Karimi A, RafieiTabatabaei S, Rajabnejad M, et al. An algorithmic approach to diagnosis and treatment of Coronavirus Disease 2019 (COVID-19) in children: iranian expert’s consensus statement. Arch Pediatr Infect Dis. 2020;8(2):e102400. doi: 10.5812/pedinfect.102400.

46. Alder Hey Children’s Hospital: Clinical management of children admitted to hospital with COVID-19. March 2020. Version 1. Available online: https://alderhey.nhs.uk/application/files/1815/8422/1173/COVID_19_IN_CHILDREN_CLINICAL_GUIDANCE_v1.pdf.

47. Michigan Medicine University of Michigan. Inpatient Guidance for treatment of COVID-19 in adults and children. Available online: http://www.med.umich.edu/asp/pdf/adult_guidelines/COVID-19-treatment.pdf.

48. WHO Coronavirus disease (COVID-2019) situation reports. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.

49. Приказ Министерства здравоохранения Российской Федерации от 19.03.2020 N 198н «О временном порядке организации работы медицинских организации в целях реализации мер по профилактике и снижению рисков распространения новой коронавирусной инфекции COVID-19» (с изменениями от 27 марта 2020 г. N 246н). Доступно по: https://rg.ru/2020/03/20/minzdravprikaz198-site-dok.html. Ссылка активна на 12.04.2020.

50. Whittaker E. et al., Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;e2010369. doi: 10.1001/jama.2020.10369/.

51. Toubiana J, Poirault C, Corsia A, et al. Outbreak of Kawasaki disease in children during COVID-19 pandemic: a prospective observational study in Paris, France. medRxiv. Preprint posted May 2020. doi: 10.1101/2020.05.10.20097394.

52. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. doi: 10.1016/S01406736(20)31094-1.

53. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2pandemic. Circulation. 2020;382:137022. doi: 10.1161/CIRCULATIONAHA.120.048360.

54. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. Published online May 13, 2020. doi: 10.1016/S0140-6736(20)31103-X.

55. Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic comment. Lancet. Published online May 13, 2020. doi: 10.1016/S0140-6736(20)31129-6.

56. European Centre for Disease Prevention and Control. Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children. Published May 15, 2020. Available online: https://www.ecdc. europa.eu/en/publicationsdata/paediatricinflammatory-multisystem-syndrome-and-sarscov-2-rapid-risk-assessment. Accessed on May 22, 2020.

57. Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. https://www.rcpch.ac.uk/resources/guidance-paediatric-multisysteminflammatory-syndrometemporally-associatedcovid-19. Accessed on May 22, 2020.

58. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Published May 15, 2020. https://www.who.int/publications-detail/multisysteminflammatorysyndrome-in-children-and-adolescents-withcovid-19. Accessed on May 22, 2020.

59. Pediatric Acute Respiratory Distress Syndrome: Consensus Recommendations From the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med. 2015;16(5):428–439. doi: 10.1097/PCC.0000000000000350.

60. Delaney M, Bell M, Smith K, et al. Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region. J Pediatr. 2020;223:199–203.e1. doi: 10.1016/j.jpeds.2020.05.007.

61. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020 May 17. doi: 10.1161/CIRCULATIONAHA.120.048360.

62. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020 May 13. doi: 10.1016/S0140-6736(20)31103-X.

63. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. doi: 10.1016/S0140-6736(20)31094-1.

64. Hennon TR, Penque MD, Abdul-Aziz R, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol. 2020 May 23:101232. doi: 10.1016/j.ppedcard.2020.101232. Epub ahead of print. PMCID: PMC7244417

65. Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123(5):e783–e789. doi: 10.1542/peds.2008-1871.